Reducing the Amount of Acetaminophen Available in Prescription Products

Acetaminophen is one of the most commonly utilized medications in the United States, and is widely available in a variety of over-the-counter (OTC) and prescription products designed to reduce pain and/or fever. more...

FDA identifies 13 medications that will be added to the watch list

The US Food and Drug Administration (FDA) continually monitors product safety information even after the FDA has granted approval. The FDA tracks and monitors post-marketing safety information and medication errors through the Adverse Event Reporting System (AERS), which is a computerized information database designed to support the FDA's post-marketing safety surveillance program for all approved drug and biologic products. Information is compiled through voluntary reporting by health care professionals and consumers. The AERS contains over four million reports of adverse events dating back to 1969. more...

Coverage of Medical Marijuana

Medical Marijuana is now legal in 14 states (Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Jersey, New Mexico, Oregon, Rhode Island, Vermont and Washington) and Washington DC as of September 2010 with many more states considering legalization. more...

Drug Shortages

There is a growing concern among healthcare providers about the increasing number of drug shortages. As of the beginning of the year almost 140 drugs are currently listed in a shortage status. Most of the drug shortages currently involve generic drugs; although there are some areas where both a brand and generic product are in shortage. more...

FDA Requires Labeling Change for All Antipsychotic Medications

On February 22, 2011, the Food and Drug Administration (FDA) announced that the labeling of all antipsychotics have changed to warn healthcare professionals about risks associated with use during pregnancy to newborns. more...

Proton Pump Inhibitor Labeling Change

On March 2nd, 2011 the Food and Drug Administration (FDA) released a drug safety communication to healthcare professionals and the public regarding proton pump inhibitors (PPI) and their potential to cause low levels of magnesium (hypomagnesemia). more...